Quality control test for immunoreactivity of radiolabeled antibody.
A rapid method for the measurement of the immunoreactive fraction of a radiolabeled monoclonal antibody or antibody fragment has been developed. This may be used as a quality control test prior to patient administration of the radiolabeled antibody preparation. The test employs solid phase antigens and the assay is conducted under conditions of antigen excess. Assay parameters have been evaluated and a standardized procedure has been developed. The assay has been compared to a standard extrapolation method and found to give approximately the same result. The test has been used on four different radiolabeled antibodies currently in clinical trials in patients with colorectal cancer. Mean immunoreactive fractions for these radiolabeled antibodies ranged from 35 to 65% and the variability of the immunoreactive fraction ranged from 140 to 240% for different antibodies. We conclude that the quality, defined as the immunoreactive fraction, of radiolabeled antibodies is both low and highly variable, indicating the need for a quality control test of these radiopharmaceuticals in the clinic prior to patient administration.
Rhodes
B A
BA
RhoMed Inc., Albuquerque, NM 87106.
Buckelew
J M
JM
Pant
K D
KD
Hinkle
G H
GH
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000032:analysis*; D000937:Antigen-Antibody Reactions; D000951:Antigens, Neoplasm / Q000276:immunology; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000032:analysis; D003110:Colonic Neoplasms / Q000032:analysis; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000032:analysis*; D011786:Quality Control; D011863:Radioimmunoassay / Q000592:standards*
D000906:Antibodies; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor